Archive for category: Latest Articles

Preoperative detection of Vesical Imaging‐Reporting and Data System (VI‐RADS) score 5 reliably identifies extravesical extension of urothelial carcinoma of the urinary bladder and predicts significant delayed time to cystectomy: time to reconsider the need for primary deep transurethral resection of bladder tumour in cases of locally advanced disease?

Abstract

We read with interest the article by Mostafid et al.(1) devoted to assessing the curative effects of chemoablation with endovescical mitomycin‐C versus surgical management in low risk non‐muscle invasive bladder cancer (defined as European Organisation for Research and Treatment of Cancer [EORTC] risk of recurrence score ≤6) with visual diagnosis of recurrence and no previous history of non‐urothelial bladder cancer or high grade /≥T1 disease.

CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin‐C vs surgical management in low‐risk non‐muscle‐invasive bladder cancer

Abstract

We read with interest the article by Mostafid et al.(1) devoted to assessing the curative effects of chemoablation with endovescical mitomycin‐C versus surgical management in low risk non‐muscle invasive bladder cancer (defined as European Organisation for Research and Treatment of Cancer [EORTC] risk of recurrence score ≤6) with visual diagnosis of recurrence and no previous history of non‐urothelial bladder cancer or high grade /≥T1 disease.

Complications after open and robot‐assisted radical prostatectomy and association with postoperative opioid use: an analysis of data from the PREVENTER trial

Abstract

We read with interest the article by Mostafid et al.(1) devoted to assessing the curative effects of chemoablation with endovescical mitomycin‐C versus surgical management in low risk non‐muscle invasive bladder cancer (defined as European Organisation for Research and Treatment of Cancer [EORTC] risk of recurrence score ≤6) with visual diagnosis of recurrence and no previous history of non‐urothelial bladder cancer or high grade /≥T1 disease.

Recurrence and Progression Free Survival of Intermediate Risk Non‐Muscle Invasive Bladder Cancer: The impact of Conditional Evaluation and Sub‐Classification

Abstract

We read with interest the article by Mostafid et al.(1) devoted to assessing the curative effects of chemoablation with endovescical mitomycin‐C versus surgical management in low risk non‐muscle invasive bladder cancer (defined as European Organisation for Research and Treatment of Cancer [EORTC] risk of recurrence score ≤6) with visual diagnosis of recurrence and no previous history of non‐urothelial bladder cancer or high grade /≥T1 disease.

Evidence‐Based Quality and Accuracy of YouTube Videos about Nephrolithiasis

Abstract

We read with interest the article by Mostafid et al.(1) devoted to assessing the curative effects of chemoablation with endovescical mitomycin‐C versus surgical management in low risk non‐muscle invasive bladder cancer (defined as European Organisation for Research and Treatment of Cancer [EORTC] risk of recurrence score ≤6) with visual diagnosis of recurrence and no previous history of non‐urothelial bladder cancer or high grade /≥T1 disease.

© 2022 BJU International. All Rights Reserved.